This page has only limited features, please log in for full access.
BACKGROUND Digital health has been advancing owing to technological progress by means of smart devices and artificial intelligence, amongst other developments. In the field of diabetes, especially, there are many active use cases of digital technology supporting the treatment of diabetes and improving lifestyle. In the innovation ecosystem, new alliance networks are formed not only by medical device companies and pharmaceutical companies, but also by information and communications technology (ICT) companies and start-ups. While understanding and utilizing the network structure is important to increase the competitive advantage of companies, there is a lack of previous research describing the structure of alliance networks and the factors that lead to their formation in digital health. OBJECTIVE The aim of this study was to explore the significance of alliance networks, focusing on digital health for diabetes, in effectively implementing processes, from the Research and Development (R&D) of products and/or services to their launch and market penetration. METHODS First, we listed the companies and contracts related to the digital health for diabetes, visualized the change in the number of companies and the connections between companies in each industry, and analyzed the overview of the network. Second, we calculated the degree, betweenness centrality, and eigenvector centrality of each company in each year. Next, we analyzed the relationship between network centrality and market competitiveness by using annual sales as a parameter of company competitiveness. We also compared the network centrality of each company by industry and/or headquarters location and analyze the characteristics of companies with higher centrality. Finally, we analyzed the relationship between network centrality and the number of products certified or approved by the U.S. Food and Drug Administration (FDA). RESULTS We found the degree centrality of companies was correlated with an increase in their sales; The betweenness and eigenvector centrality of medical device companies located in the U.S. were significantly higher than those outside the U.S; Finally, the degree, betweenness and eigenvector centralities were correlated with an increase in the number of Class III, but not of Class I nor II medical device products. CONCLUSIONS These findings give rise to new insights on the industry ecosystem for digital health and its requirement and expect a contribution to R&D practices in the field of digital health.
Satoru Kikuchi; Kota Kodama; Shintaro Sengoku. Significance of Strategic Alliance in Research and Development of Digital Health Products for Diabetes (Preprint). 2021, 1 .
AMA StyleSatoru Kikuchi, Kota Kodama, Shintaro Sengoku. Significance of Strategic Alliance in Research and Development of Digital Health Products for Diabetes (Preprint). . 2021; ():1.
Chicago/Turabian StyleSatoru Kikuchi; Kota Kodama; Shintaro Sengoku. 2021. "Significance of Strategic Alliance in Research and Development of Digital Health Products for Diabetes (Preprint)." , no. : 1.
Scientific research has been facing the problem of increase in size and complexity. Hence, the utilization of scientometric methodology for management of science has been expected because of needs for strategic and organizational management of basic and academic scientific research. Present study focuses on collaboration and knowledge structures in an interdisciplinary research project and proposes an evaluation framework to assist data-driven decision-making in scientific research by measuring the complexity of these structures. Co-author and co-word networks were constructed from the bibliographic information of publications generated in an interdisciplinary research project, and cross-sectional and longitudinal analyses of complexity were conducted by calculating the graph entropy. Observations of these networks demonstrated the different structural features and modes of time evolution. The results of the cross-sectional analysis indicated that the correlations between the amount of change in these complexities suggested the possibility of induction in the knowledge structure by the collaboration structure. The results of the longitudinal analysis informed that the decrease in the increment of complexity over time reflected the transition of observed case's strategy from promoting interdisciplinary research to the integration of research outcomes to realize the vision. The proposed framework will allow to implement real-time and evidence-based management practices in scientific research.
Shuto Miyashita; Shintaro Sengoku. Scientometrics for management of science: collaboration and knowledge structures and complexities in an interdisciplinary research project. Scientometrics 2021, 126, 7419 -7444.
AMA StyleShuto Miyashita, Shintaro Sengoku. Scientometrics for management of science: collaboration and knowledge structures and complexities in an interdisciplinary research project. Scientometrics. 2021; 126 (9):7419-7444.
Chicago/Turabian StyleShuto Miyashita; Shintaro Sengoku. 2021. "Scientometrics for management of science: collaboration and knowledge structures and complexities in an interdisciplinary research project." Scientometrics 126, no. 9: 7419-7444.
This study investigated a case of Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), a tumor profiling test approved by the U.S. Food and Drug Administration (FDA) in 2017, to examine what factors would contribute to healthcare innovation. First, we set the following three parameters to observe cases: (i) the FDA regulatory reforms, (ii) early application of new technologies, such as next-generation sequencing (NGS), to both research and clinical settings, and (iii) accumulation of open data. Then, we performed a comparative analysis of MSK-IMPACT with FoundationOne CDx and Oncomine Dx Target Test, both of which were FDA-approved tumor profiling tests launched in 2017. As a result, we found that MSK-IMPACT secures neutrality as a non-profit organization, achieves the active incorporation of basic research results, and performs superiorly in clinical operations, such as patient enrollment. On the contrary, we confirmed that FoundationOne CDx was the most prominent case in terms of the number of new drugs and expanded indications approved in which the FDA’s expedited approval programs were considerably utilized. Consequently, to uncover the full potential of MSK-IMPACT, it is suggested that more intersectoral collaborative activities between various healthcare stakeholders, in particular, pharmaceutical companies, for driving clinical development must be carried out based on an organizational framework that facilitates collaboration.
Takaharu Jibiki; Hayato Nishimura; Shintaro Sengoku; Kota Kodama. Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care. Cancers 2021, 13, 3448 .
AMA StyleTakaharu Jibiki, Hayato Nishimura, Shintaro Sengoku, Kota Kodama. Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care. Cancers. 2021; 13 (14):3448.
Chicago/Turabian StyleTakaharu Jibiki; Hayato Nishimura; Shintaro Sengoku; Kota Kodama. 2021. "Regulations, Open Data and Healthcare Innovation: A Case of MSK-IMPACT and Its Implications for Better Cancer Care." Cancers 13, no. 14: 3448.
BACKGROUND A construction method has emerged in which a camera is installed around a construction machine, and the operator remotely controls the machine while synchronizing the vibration of the machine with the images seen from the operator's seat using virtual reality (VR) technology. Indices related to changes in heart rate and physical vibration, such as heart rate variability (HRV) and multiscale entropy (MSE), can then be measured in the operators. As these indices are quantitative measures of autonomic regulation in the cardiovascular system, they can provide a useful means of assessing operational stress. OBJECTIVE This study aimed to improve the efficiency of machine operation by evaluating the changes in the heart rate and body vibration of the machine operators, while considering the psychological load on the operators. METHODS Nine remote operators (18–48 years old) participated in the experiment, which involved 42 measurements. A construction machine was driven on a test course simulating a construction site, and three patterns of operation—riding operation of the machine, remote operation using monitor images, and VR operation combining monitor images and machine vibration—were compared. The heartbeat, body vibration, and driving time of the participants were measured using a sensing wear made of woven film-like conductive material and a 3-axis acceleration measurement device (WHS-2). We used HRV analysis in the time and frequency domains, MSE analysis as a measure of the complexity of heart rate changes, and the ISO 2631 vibration index. Multiple regression analysis was used to model the relationship between HRV low frequency (LF)/high frequency (HF), MSE, vibration index, and driving time of construction equipment. Efficient driving time was investigated with a focus on stress reduction. RESULTS Multiple comparisons using the Bonferroni test and Kruskal-Wallis test showed statistically significant differences (P=.05) in HRV-LF/HF, the vibration indices Aw and motion sickness dose value (MSDV), and driving time among the three operation patterns. The riding operation was found to reduce the driving time of the machine, but the operation stress was the highest in this case; operation by the monitor image was found to have the lowest operation stress but the longest operation time. Multiple regression analysis showed that the explanatory variables (LH/HF), R-R interval (RRI), and vibration index (MSDVz by vertical oscillation of 0.5–5 Hz) had a negative effect on driving time (adjusted R2=0.449). CONCLUSIONS A new method was developed to calculate the appropriate operating time by considering operational stress and suppressing the physical vibration within an acceptable range. By focusing on the relationship between psychological load and physical vibration, which has left unexplored in previous studies, the relationship of these variables with the driving time of construction machines was clarified.
Nobuki Hashiguchi; Jianfei Cao; Yeongjoo Lim; Shinichi Kuroishi; Yasuhiro Miyazaki; Shigeo Kitahara; Shintaro Sengoku; Kota Kodama. Psychological Effects of Heart Rate and Physical Vibration on the Operation of Construction Machine: An Experimental Study (Preprint). 2021, 1 .
AMA StyleNobuki Hashiguchi, Jianfei Cao, Yeongjoo Lim, Shinichi Kuroishi, Yasuhiro Miyazaki, Shigeo Kitahara, Shintaro Sengoku, Kota Kodama. Psychological Effects of Heart Rate and Physical Vibration on the Operation of Construction Machine: An Experimental Study (Preprint). . 2021; ():1.
Chicago/Turabian StyleNobuki Hashiguchi; Jianfei Cao; Yeongjoo Lim; Shinichi Kuroishi; Yasuhiro Miyazaki; Shigeo Kitahara; Shintaro Sengoku; Kota Kodama. 2021. "Psychological Effects of Heart Rate and Physical Vibration on the Operation of Construction Machine: An Experimental Study (Preprint)." , no. : 1.
Nobuki Hashiguchi; Jianfei Cao; Yeongjoo Lim; Shinichi Kuroishi; Yasuhiro Miyazaki; Shigeo Kitahara; Shintaro Sengoku; Katsushi Matsubayashi; Kota Kodama. Psychological Effects of Heart Rate and Physical Vibration on the Operation of Construction Machine: An Experimental Study (Preprint). JMIR mHealth and uHealth 2021, 1 .
AMA StyleNobuki Hashiguchi, Jianfei Cao, Yeongjoo Lim, Shinichi Kuroishi, Yasuhiro Miyazaki, Shigeo Kitahara, Shintaro Sengoku, Katsushi Matsubayashi, Kota Kodama. Psychological Effects of Heart Rate and Physical Vibration on the Operation of Construction Machine: An Experimental Study (Preprint). JMIR mHealth and uHealth. 2021; ():1.
Chicago/Turabian StyleNobuki Hashiguchi; Jianfei Cao; Yeongjoo Lim; Shinichi Kuroishi; Yasuhiro Miyazaki; Shigeo Kitahara; Shintaro Sengoku; Katsushi Matsubayashi; Kota Kodama. 2021. "Psychological Effects of Heart Rate and Physical Vibration on the Operation of Construction Machine: An Experimental Study (Preprint)." JMIR mHealth and uHealth , no. : 1.
BACKGROUND Smartphones have become an integral part of our lives with their unprecedented popularity and diversification of applications. The continuous upgrading of information technology has also enabled smartphones to display great potential in the field of healthcare. OBJECTIVE This study aimed to clarify the future research direction of mHealth by analyzing its research trends and latest research hotspots. METHODS This study collected mHealth-related literature published between 2000 and 2020 from the Web of Science database. Descriptive statistics of the literature were computed using Excel software. The publication trends of mHealth research were determined by analyzing the annual number of publications in the literature and annual number of publications categorized based on different countries. Finally, this study used the VOSviewer tool to construct visualization network maps of country/region collaborations and author keyword co-occurrences, and overlay visualization maps of the average publication year of author keywords to analyze the hotspots and research trends in mHealth research. RESULTS In this study, 12,593 mHealth-related research articles published between 2000 and 2020 were collected. The results showed an exponential growth trend in the number of annual publications in mHealth literature. The United States remained the leading contributor to the literature in this area (5,294/12,593, 42%), well ahead of other countries/regions. Other countries/regions also showed a clear trend of annual increases in the number of publications in mHealth literature. Regarding cooperation between countries, the four countries with the largest number of publications, the United States, the United Kingdom, Canada, and Australia, were found to cooperate more closely. The rest of the countries/regions showed a clear geographical pattern of cooperation. The keyword co-occurrence analysis of the top 100 authors formed five clusters, namely: development of mHealth medical technology and its application in various diseases, use of mHealth technology to improve basic public health and health policy, mHealth self-health testing and management in daily life, adolescent use of mHealth, and mHealth in mental health. The research trends revealed a gradual shift in mHealth research from health policy and improving public healthcare to the development and social application of mHealth technologies. CONCLUSIONS To the best of our knowledge, the most current bibliometric analysis dates back to 2016. However, the number of mHealth researches published between 2017 and 2020 exceeds the previous total. Therefore, the results of this study shed light on the latest research hotspots and research trends in mHealth research. These findings provide a useful overview of the development of the field; they may also serve as a valuable reference and provide guidance for other researchers in the field.
Jianfei Cao; Yeongjoo Lim; Shintaro Sengoku; Xitong Guo; Kota Kodama. A Paradigm Shift in Healthcare Innovation as Revealed by Research Trends in Mobile Health: A Bibliometric Analysis. (Preprint). 2021, 1 .
AMA StyleJianfei Cao, Yeongjoo Lim, Shintaro Sengoku, Xitong Guo, Kota Kodama. A Paradigm Shift in Healthcare Innovation as Revealed by Research Trends in Mobile Health: A Bibliometric Analysis. (Preprint). . 2021; ():1.
Chicago/Turabian StyleJianfei Cao; Yeongjoo Lim; Shintaro Sengoku; Xitong Guo; Kota Kodama. 2021. "A Paradigm Shift in Healthcare Innovation as Revealed by Research Trends in Mobile Health: A Bibliometric Analysis. (Preprint)." , no. : 1.
Jianfei Cao; Yeongjoo Lim; Shintaro Sengoku; Xitong Guo; Kota Kodama. Exploring the Shift in International Trends in Mobile Health Research: A Bibliometric Analysis from 2000 to 2020 (Preprint). JMIR mHealth and uHealth 2021, 1 .
AMA StyleJianfei Cao, Yeongjoo Lim, Shintaro Sengoku, Xitong Guo, Kota Kodama. Exploring the Shift in International Trends in Mobile Health Research: A Bibliometric Analysis from 2000 to 2020 (Preprint). JMIR mHealth and uHealth. 2021; ():1.
Chicago/Turabian StyleJianfei Cao; Yeongjoo Lim; Shintaro Sengoku; Xitong Guo; Kota Kodama. 2021. "Exploring the Shift in International Trends in Mobile Health Research: A Bibliometric Analysis from 2000 to 2020 (Preprint)." JMIR mHealth and uHealth , no. : 1.
In recent years, technological progress in smart devices and artificial intelligence has also led to advancements in digital health. Digital health tools are especially prevalent in diabetes treatment and improving lifestyle. In digital health’s innovation ecosystem, new alliance networks are formed not only by medical device companies and pharmaceutical companies but also by information and communications technology (ICT) companies and start-ups. Therefore, while focusing on digital health for diabetes, this study explored the characteristics of companies with high network centralities. Our analysis of the changes in degree, betweenness, and eigenvector centralities of the sample companies from 2011 to 2020 found drastic changes in the company rankings of those with high network centrality during this period. Accordingly, the following eight companies were identified and investigated as the top-ranking technology sector companies: IBM Watson Health, Glooko, DarioHealth, Welldoc, OneDrop, Fitbit, Voluntis, and Noom. Lastly, we characterized these cases into three business models: (i) intermediary model, (ii) substitute model, and (iii) direct-to-consumer model, and we analyzed their customer value.
Satoru Kikuchi; Kota Kadama; Shintaro Sengoku. Characteristics and Classification of Technology Sector Companies in Digital Health for Diabetes. Sustainability 2021, 13, 4839 .
AMA StyleSatoru Kikuchi, Kota Kadama, Shintaro Sengoku. Characteristics and Classification of Technology Sector Companies in Digital Health for Diabetes. Sustainability. 2021; 13 (9):4839.
Chicago/Turabian StyleSatoru Kikuchi; Kota Kadama; Shintaro Sengoku. 2021. "Characteristics and Classification of Technology Sector Companies in Digital Health for Diabetes." Sustainability 13, no. 9: 4839.
Biotech startup firms developing pharmaceutical seeds from scientific and technological innovation are burdened by significant Research & Development (R&D) expenses, long-term R&D operations, and low probability of R&D success. To address these challenges while sustainably creating innovations and new drugs, business alliances with existing pharmaceutical companies are one of the most important issues on the management agenda. The present study explores the necessity and significance of business alliances with pharmaceutical companies for the development of drug-discovery by Japanese biotech startup firms under high uncertainty. This study investigates the types of alliances to understand the origins of sustainability of these creative activities. First, we investigate and analyze the details of the partnership and its impact on the products under development based on the publicly available information of 16 drug discovery biotech startup firms in Japan that had become public since 2010. As a result, all firms continued their operations with the funds obtained from the business alliances with pharmaceutical firms at the time of their initial public offering (IPO). In addition, 56% of these firms’ alliance projects (n = 73) were seeded-out, and 32% seeded-in, indicating that they had adopted flexible alliance strategies not limited to seed-out ones. For sustainable going concern of the biotech startup business, it is valuable to consider multiple strategic options: “in-licensing and value up”, “best-in-class”, “platform leadership” and “first-in-class” depending on the characteristics of seeds and environmental restrictions.
Yoshimi Harada; Huayi Wang; Kota Kodama; Shintaro Sengoku. Drug Discovery Firms and Business Alliances for Sustainable Innovation. Sustainability 2021, 13, 3599 .
AMA StyleYoshimi Harada, Huayi Wang, Kota Kodama, Shintaro Sengoku. Drug Discovery Firms and Business Alliances for Sustainable Innovation. Sustainability. 2021; 13 (7):3599.
Chicago/Turabian StyleYoshimi Harada; Huayi Wang; Kota Kodama; Shintaro Sengoku. 2021. "Drug Discovery Firms and Business Alliances for Sustainable Innovation." Sustainability 13, no. 7: 3599.
Large-scale, publicly funded research and development (R&D) programs are implemented to accelerate state-of-the-art science, technology, and innovation applications that are expected to solve various societal problems. The present study aims to build on the body of theory on the mechanisms that promote or impede the creation of intellectual property in such programs. Using a mixed methods approach and combining quantitative network analysis and qualitative semistructured interviews, we conducted a case study to investigate best practices in terms of intellectual property creation in a Japanese governmental research and development program. The results of the network analysis showed that the core/periphery structure in the co-inventor network of patents and joint application by a university and a startup promoted intellectual property creation. The results of the interview confirmed the significance of a reciprocal mindset, which the researchers in academia could acquire through collaboration with a startup. These results suggest that a knowledge logistics system for agile intellectual property management can be established by learning to acquire tacit knowledge on social implementation. Furthermore, we focus on the principal–agent relationship between knowledge producers and knowledge consumers as a factor that impedes the creation of intellectual property. We also discuss adverse selection and moral hazards caused by information asymmetry between knowledge producers and knowledge consumers and how to deal with them.
Shuto Miyashita; Shogo Katoh; Tomohiro Anzai; Shintaro Sengoku. Intellectual Property Management in Publicly Funded R&D Program and Projects: Optimizing Principal–Agent Relationship through Transdisciplinary Approach. Sustainability 2020, 12, 9923 .
AMA StyleShuto Miyashita, Shogo Katoh, Tomohiro Anzai, Shintaro Sengoku. Intellectual Property Management in Publicly Funded R&D Program and Projects: Optimizing Principal–Agent Relationship through Transdisciplinary Approach. Sustainability. 2020; 12 (23):9923.
Chicago/Turabian StyleShuto Miyashita; Shogo Katoh; Tomohiro Anzai; Shintaro Sengoku. 2020. "Intellectual Property Management in Publicly Funded R&D Program and Projects: Optimizing Principal–Agent Relationship through Transdisciplinary Approach." Sustainability 12, no. 23: 9923.
An important agenda of pharmaceutical companies is the establishment of therapeutic area strategies, drug modality, and geographic strategies for research and development. It is worthwhile to understand the changes in therapeutic area, modality and internationalization of the top-selling pharmaceutical drugs over the past. Hence, the purposes of this study are to investigate changes in therapeutic area, modality and internationalization of the top-selling drugs and to identify their life cycle patterns. We compared the top-selling drugs between 2011 and 2017, and found that the percentages of nichebuster cancer drugs and home region-oriented drugs have increased whereas the proportions of traditional blockbuster cardiovascular drugs and global drugs have decreased. We compared product life cycle patterns via a Kruskal–Wallis test, and identified the features of product life cycle patterns per therapeutic area and modality. We performed a case study on drugs in the same class with the same pharmacological mechanism but found no differences across cases. Our results provide insights into therapeutic area strategies that consider life cycle patterns and geographic strategies that consider the competitive advantages of home region-oriented drugs. Finally, we presented new and simple models of life cycle patterns. This approach may help such enterprises establish and maintain sustainable growth.
Fumio Teramae; Tomohiro Makino; Shintaro Sengoku; Yeongjoo Lim; Takashi Natori; Kota Kodama. Research on Pharmaceutical Product Life Cycle Patterns for Sustainable Growth. Sustainability 2020, 12, 8938 .
AMA StyleFumio Teramae, Tomohiro Makino, Shintaro Sengoku, Yeongjoo Lim, Takashi Natori, Kota Kodama. Research on Pharmaceutical Product Life Cycle Patterns for Sustainable Growth. Sustainability. 2020; 12 (21):8938.
Chicago/Turabian StyleFumio Teramae; Tomohiro Makino; Shintaro Sengoku; Yeongjoo Lim; Takashi Natori; Kota Kodama. 2020. "Research on Pharmaceutical Product Life Cycle Patterns for Sustainable Growth." Sustainability 12, no. 21: 8938.
Good manufacturing practice (GMP) is advocated and implemented as a standardized procedure for manufacturing dietary supplements. However, in Japan as a case, only half of the manufacturers in this field so far adopt it. To address this issue, the present study aims to explore the effect of key characteristics of a company on the adoption of and compliance with GMP for dietary supplements. The focus is on the effect of expertise in the pharmaceutical industry. The relationships between company characteristics and the adoption of GMP were analyzed for 90 manufacturers in the dietary supplement industry in Japan. A binomial logistic regression analysis showed that each of the following three factors had a positive and significant effect on the company’s adoption of GMP: company size in terms of revenue (odds ratio = 1.04, p = 0.019), possession of a manufacturing license for pharmaceutical products (13.7, p = 0.003), and number of own product categories manufactured (3.93, p = 0.00009). These findings strongly suggest that the company’s manufacturing capability of pharmaceutical products works as a key driver for the better adoption of a quality standard in the dietary supplement industry in Japan. Few considerations were made for conditions of the adoption and implementation of GMP. The present study empirically contributes by providing key clues for issues in the dietary supplement industry and by forming a theoretical base for policymakers and the regulatory authorities.
Keigo Sato; Kota Kodama; Shintaro Sengoku. Corporate Characteristics and Adoption of Good Manufacturing Practice for Dietary Supplements in Japan. International Journal of Environmental Research and Public Health 2020, 17, 4748 .
AMA StyleKeigo Sato, Kota Kodama, Shintaro Sengoku. Corporate Characteristics and Adoption of Good Manufacturing Practice for Dietary Supplements in Japan. International Journal of Environmental Research and Public Health. 2020; 17 (13):4748.
Chicago/Turabian StyleKeigo Sato; Kota Kodama; Shintaro Sengoku. 2020. "Corporate Characteristics and Adoption of Good Manufacturing Practice for Dietary Supplements in Japan." International Journal of Environmental Research and Public Health 17, no. 13: 4748.
There have been prior attempts to utilize machine learning to address issues in the medical field, particularly in diagnoses using medical images and developing therapeutic regimens. However, few cases have demonstrated the usefulness of machine learning for enhancing health consciousness of patients or the public in general, which is necessary to cause behavioral changes. This paper describes a novel case wherein the uptake rate for colorectal cancer examinations has significantly increased due to the application of machine learning and nudge theory. The paper also discusses the effectiveness of social impact bonds (SIBs) as a scheme for realizing these applications. During a healthcare SIB project conducted in the city of Hachioji, Tokyo, machine learning, based on historical data obtained from designated periodical health examinations, digitalized medical insurance receipts, and medical examination records for colorectal cancer, was used to deduce segments for whom the examination was recommended. The result revealed that out of the 12,162 people for whom the examination was recommended, 3264 (26.8%) received it, which exceeded the upper expectation limit of the initial plan (19.0%). We conclude that this was a successful case that stimulated discussion on potential further applications of this approach to wider regions and more diseases.
Daitaro Misawa; Jun Fukuyoshi; Shintaro Sengoku. Cancer Prevention Using Machine Learning, Nudge Theory and Social Impact Bond. International Journal of Environmental Research and Public Health 2020, 17, 790 .
AMA StyleDaitaro Misawa, Jun Fukuyoshi, Shintaro Sengoku. Cancer Prevention Using Machine Learning, Nudge Theory and Social Impact Bond. International Journal of Environmental Research and Public Health. 2020; 17 (3):790.
Chicago/Turabian StyleDaitaro Misawa; Jun Fukuyoshi; Shintaro Sengoku. 2020. "Cancer Prevention Using Machine Learning, Nudge Theory and Social Impact Bond." International Journal of Environmental Research and Public Health 17, no. 3: 790.
Japan officially introduced cost-effectiveness analysis (CEA) in 2019, whereas some countries, such as England, Sweden, Canada, and Australia, have experience with health technology assessment (HTA). Therefore, there are few reports that comprehensively examine the situation of health economic evaluation in Japan. In this paper, we review the health economic evaluation systems among those countries. We also conducted a case study that investigated the time-trend of cost, effectiveness, and incremental cost-effectiveness ratio (ICER) for anticancer drug regimens in Japan. We found a time-trend ICER for breast cancer (BC). Additionally, molecular targeting drugs for BC had a positive effect on the ICER, and both small molecular-targeting drugs and monoclonal antibodies (mAb) had a higher ICER for BC compared with conventional drugs. Finally, we discuss a possible way to implement a health economic evaluation system in Japan.
Fumio Teramae; Naoya Yamaguchi; Tomohiro Makino; Shintaro Sengoku; Kota Kodama. Holistic cost-effectiveness analysis of anticancer drug regimens in Japan. Drug Discovery Today 2019, 25, 269 -273.
AMA StyleFumio Teramae, Naoya Yamaguchi, Tomohiro Makino, Shintaro Sengoku, Kota Kodama. Holistic cost-effectiveness analysis of anticancer drug regimens in Japan. Drug Discovery Today. 2019; 25 (2):269-273.
Chicago/Turabian StyleFumio Teramae; Naoya Yamaguchi; Tomohiro Makino; Shintaro Sengoku; Kota Kodama. 2019. "Holistic cost-effectiveness analysis of anticancer drug regimens in Japan." Drug Discovery Today 25, no. 2: 269-273.
Entry into a new therapeutic area, that is, one in which a pharmaceutical firm lacks experience, is a considerable challenge for firms that need to overcome scientific and technological barriers. To address this issue, the present study aims to explore the potentiality of alliances in an empirical manner. From the clinical trials sponsored by 20 major pharmaceutical firms during 2008–2016 listed at ClinicalTrials.gov (n = 14,941 clinical trials), cases of entering a new therapeutic area for a pharmaceutical firm were extracted (n = 73), followed by statistical analyses to evaluate the effect of alliances in this regard. We found that the average number of participating organizations in the cases of entering a new therapeutic area was significantly larger than that in the cases of entering an area in which firms had experience (P < .01), suggesting that alliance has a positive effect on new therapeutic entry for these pharmaceutical firms. Second, we found that the cases of partnering with nonindustrial or nongovernmental organizations (ie, universities, research institutes, hospitals, funding agencies, and others; n = 32 of the 73) were significantly associated with these new entry trials (adjusted odds ratio = 1.1, P < .05). Furthermore, we identified that 10 of the 32 clinical trials were associated with rare diseases, which is an overrepresentation compared to the occurrence in the universe (1015 of the 14,941; P < 10–5). These findings strongly suggest the importance of alliances with diversified partners in new therapeutic entry and also provide a basis for further detailed investigation of key success factors for pharmaceutical firms.
Kinya Okada; Shintaro Sengoku. Entry Into New Therapeutic Areas: The Effect of Alliance on Clinical Trials. Therapeutic Innovation & Regulatory Science 2019, 53, 648 -653.
AMA StyleKinya Okada, Shintaro Sengoku. Entry Into New Therapeutic Areas: The Effect of Alliance on Clinical Trials. Therapeutic Innovation & Regulatory Science. 2019; 53 (5):648-653.
Chicago/Turabian StyleKinya Okada; Shintaro Sengoku. 2019. "Entry Into New Therapeutic Areas: The Effect of Alliance on Clinical Trials." Therapeutic Innovation & Regulatory Science 53, no. 5: 648-653.
Developing high-tech start-ups has been embedded into political efforts that require a large, long-term investment whereas the uncertainty of research and development and the business risks are high. In the biotechnology and healthcare field, the emergence of new modalities such as cell and gene therapy and nanomedicine need to be implemented complying multidimensional societal requirements that covers ethics, regulations and adoption by the citizens. Considering these issues, the present chapter aims to explore a unique and optimal innovation model for regional biotech industry in Japan—the research and development consortium from the viewpoints of the theories of organisation on inter-firm collaboration, regional innovation system and intellectual property management. Next, cases of entrepreneurial and innovative activities around drug discovery firms in Japan to date are provided, focusing on the fields of advanced science and technology and the way to develop entrepreneurs and start-up firms from the perspective of sectorial and regional innovation systems. In the third section, in order to specifically examine the challenges and measures for developing drug discovery firms in Japan, a case of newly developed biotech cluster is examined. Conclusively, a view on the direction for boosting biotech innovation suitable to the environment is proposed, with particular foci on two non-technological elements—the design of implementation ecosystem with an R&D consortium and entrepreneurs, and the significance of socioeconomic forms of organisation in order to develop technologies properly with high ethical, regulatory and scientific linkages.
Shintaro Sengoku. Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry. Advances in Happiness Research 2019, 141 -171.
AMA StyleShintaro Sengoku. Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry. Advances in Happiness Research. 2019; ():141-171.
Chicago/Turabian StyleShintaro Sengoku. 2019. "Consortium-Based Open Innovation: Exploring a Unique and Optimal Model for Regional Biotechnology Industry." Advances in Happiness Research , no. : 141-171.
Daitaro Misawa; Shintaro Sengoku. Social Impact Bonds: Current Context and Implementation Model in the Healthcare Industry. 2019 Portland International Conference on Management of Engineering and Technology (PICMET) 2019, 1 .
AMA StyleDaitaro Misawa, Shintaro Sengoku. Social Impact Bonds: Current Context and Implementation Model in the Healthcare Industry. 2019 Portland International Conference on Management of Engineering and Technology (PICMET). 2019; ():1.
Chicago/Turabian StyleDaitaro Misawa; Shintaro Sengoku. 2019. "Social Impact Bonds: Current Context and Implementation Model in the Healthcare Industry." 2019 Portland International Conference on Management of Engineering and Technology (PICMET) , no. : 1.
Takeshi Akiyama; Shintaro Sengoku. The Productivity of Drug Development: A Systematic Review. 2019 Portland International Conference on Management of Engineering and Technology (PICMET) 2019, 1 .
AMA StyleTakeshi Akiyama, Shintaro Sengoku. The Productivity of Drug Development: A Systematic Review. 2019 Portland International Conference on Management of Engineering and Technology (PICMET). 2019; ():1.
Chicago/Turabian StyleTakeshi Akiyama; Shintaro Sengoku. 2019. "The Productivity of Drug Development: A Systematic Review." 2019 Portland International Conference on Management of Engineering and Technology (PICMET) , no. : 1.
Yoshimi Harada; Shintaro Sengoku. The Key Success Factors of Biotech Start-Up Firms: Characteristics and Attributes of the Management Teams of High-Performing Biotech Start-Ups. 2019 Portland International Conference on Management of Engineering and Technology (PICMET) 2019, 1 .
AMA StyleYoshimi Harada, Shintaro Sengoku. The Key Success Factors of Biotech Start-Up Firms: Characteristics and Attributes of the Management Teams of High-Performing Biotech Start-Ups. 2019 Portland International Conference on Management of Engineering and Technology (PICMET). 2019; ():1.
Chicago/Turabian StyleYoshimi Harada; Shintaro Sengoku. 2019. "The Key Success Factors of Biotech Start-Up Firms: Characteristics and Attributes of the Management Teams of High-Performing Biotech Start-Ups." 2019 Portland International Conference on Management of Engineering and Technology (PICMET) , no. : 1.
Newly emerging therapeutic technologies have the potential to reconfigure the understanding, diagnosis, and treatment of diseases, and, consequently, to impact human health. This study integrates co-evolutionary and system-oriented perspectives to investigate factors influencing the way emerging therapies evolve in their attempt to become established medical practices. We examined the case of the use of induced pluripotent stem (iPS) cell-based therapies for age-related macular degeneration (AMD) disease. Cell therapy evolution is explored by considering their constitutive components, namely disease, biomedical technologies, and clinical practices, and observing the changes experienced by their underlying knowledge structures. We adopted a mixed methods approach that simultaneously uses publication, patent, and clinical trial data. Our results highlight the significance of the diversity of technological possibilities, the role of subjective issues in the selection of directions of search, the complementary nature between established and emerging therapies, and the tight product-process interdependencies. This study contributes to an understanding of the difficulties encountered during the emergence of new cell therapies, and the ways in which such difficulties can be circumvented to establish effective and safe cell-based clinical practices.
Alfonso Avila-Robinson; Nazrul Islam; Shintaro Sengoku. Co-evolutionary and systemic study on the evolution of emerging stem cell-based therapies. Technological Forecasting and Social Change 2018, 138, 324 -339.
AMA StyleAlfonso Avila-Robinson, Nazrul Islam, Shintaro Sengoku. Co-evolutionary and systemic study on the evolution of emerging stem cell-based therapies. Technological Forecasting and Social Change. 2018; 138 ():324-339.
Chicago/Turabian StyleAlfonso Avila-Robinson; Nazrul Islam; Shintaro Sengoku. 2018. "Co-evolutionary and systemic study on the evolution of emerging stem cell-based therapies." Technological Forecasting and Social Change 138, no. : 324-339.